How InterX Therapy is unique.

InterX has US, EU, and Australian patents on our technology. Here are some key words within these patents which discuss our uniqueness:

  • "Neuro Stimulation": This means stimulation of nerves in cases where the signal to the brain has been interrupted. Another definition "helping the nervous system to remember."
  • "Non-invasive", "transcutaneous": This means that the electrical signal to the brain travels along the exterior of the skin, which can tingle sometimes. Most other medical devices send their electrical current through the body, which can be painful. A higher level of electrical stimulation is possible when current travels across the skin.
  • "Self-directing": InterX devices tell you the location of the best spot on the skin area to treat
  • "Multiple devices and accessories". Treatment with multiple devices and accessories accelerates the healing process.

Clinical studies:

A number of InterX clinical studies have been done in the U.S., Great Britain, Italy, Russia, and Australia. All measured pain reduction. Several also measured reduction in pain medication and length of hospitalization required.

Shown below in detail are those studies which meet a higher level of research quality. Controlled, Randomized, 60 or more patients, Published

Clinical evidence level 1
    Improvements measured
  • Reduction in pain
  • Reduction in medication

Clinical evidence level 1
    Improvements measured
  • Reduction in pain
  • Reduction in medication
  • Increased range of motion
  • Reduced edema

Clinical evidence level 2
    Improvements measured
  • Reduction in pain
  • Reduction in medication
  • Patient satisfaction

Country Italy

Tiziano Marovino (DPT,MPH, DAIPM), writing in the October 2020 issue of Practical Pain Management (link below) is in the process of evaluating the InterX 5002 device, and describes his efforts to recruit patients for a trial group with both the InterX device and a sham device to control for placebo. He states: “it is important to note that it was next to impossible to recruit patients who had experienced InterX prior to our receiving the sham unit into the comparative trial because they simply said their sessions were too valuable and did not want to risk not getting the actual treatment. As a result we had to recruit patients who were unfamiliar with the device for our comparative trial…” https://www.practicalpainmanagement.com/treatments/interventional/stimulators/product-review-non-invasive-neuromodulation-treatment-most-dif

Read More

Clinical evidence level Not Listed
    Improvements measured
  • Reduction in pain
  • Reduction in medication
  • Increased range of motion
  • Reduced hospital stay

Country UK

61 patient study
Results: The effects varied slightly between male and female patients. Males took more medication than females in both the active and the sham groups. However, there was a reduction of medication in the active groups compared to sham. While still maintaining a low pain score comparable with sham patients taking more medication, male patients in the active group reduced their medication intake by 34% and female patients reduced their medication intake by 16%. Patients in the active group were discharged on average 1.2 days earlier than the sham group. We conclude that this technology warrants further investigation and there is use for InterX® in the management of pain after total hip arthroplasty. The financial implications of reduced rehabilitation time are of significant value as healthcare costs come under greater scrutiny and pressures.

Read More

Clinical evidence level Not Listed
    Improvements measured
  • Reduction in pain
  • Reduction in medication
  • Patient satisfaction

Country Russia

https://pubmed.ncbi.nlm.nih.gov/17998187/

This 60 patient study showed improvements in pain, walking, sleep, enjoyment of life, mood, and overall assessment of outcome by an orthopedic surgeon.

Read More